MarketPulse

oral small-molecule

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Structure Therapeutics Inc.

Structure Therapeutics' Aleniglipron Posts Blockbuster Phase 2 Data, Rivaling Injectable GLP-1s

Structure Therapeutics reports Phase 2 data for oral GLP-1 agonist aleniglipron showing 16.3% weight loss, matching injectable competitors with better tolerability.
GPCRPhase 2 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Septerna's SEP-631 Shows Promise in Mast Cell Disease Treatment

Septerna reports positive Phase 1 data for SEP-631, an experimental oral treatment for mast cell-driven diseases, with plans for Phase 2b development beginning late 2026.
SEPNchronic spontaneous urticariaoral small-molecule
GlobeNewswire Inc.GlobeNewswire Inc.··Patentvest

Patent Strength, Not Clinical Data, to Drive GLP-1 Market Leadership

Patent strength, not clinical efficacy, will drive GLP-1 market leadership as clinical outcomes converge. Companies with robust IP portfolios may capture disproportionate market share despite comparable results.
PFELLYNVORHHBYAZN+2GLP-1 drugsoral small-molecule